Patrice R.
- Country
- France
- Department
- Endocrinology
Research Overview
- Phase 3 Randomized Double‑Masked Placebo‑Controlled Study of Subcutaneous Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs
- Evaluation of Crinecerfont (NBI-74788) Efficacy and Safety in Adults with Classic Congenital Adrenal Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled Trial
- Phase III Multicenter Trial Comparing Systematic Versus Serum Tg and RAI Scintigraphy-Guided Radioiodine Therapy in Intermediate-Risk Differentiated Thyroid Cancer
Data & Insights
Has run more than one trial at 43 of 157 partner sites.
Specializations
Thyroid Cancer Research
Specializes in investigating treatment approaches for various forms of thyroid cancer, particularly focusing on differentiated thyroid cancer and medullary thyroid cancer.
- Radioiodine treatment strategies
- RET-mutant cancer therapies
- Bone metastatic management
Explores innovative treatment protocols for patients with advanced thyroid carcinomas, including those with radioiodine-refractory disease.
Thyroid Eye Disease Studies
Conducts research into novel therapeutic approaches for thyroid eye disease (TED), with particular emphasis on investigating new biological treatments.
- IGF-1 receptor targeted therapies
- Proptosis reduction treatments
- Long-term disease management
Evaluates the efficacy of innovative monoclonal antibody treatments in addressing ocular manifestations of thyroid disease.
Endocrine Disorders
Investigates treatments for complex endocrine conditions, with specific focus on Classic Congenital Adrenal Hyperplasia (CAH).
- Glucocorticoid optimization
- Adrenal steroid regulation
- Novel therapeutic compounds
Studies innovative approaches to hormone regulation and metabolic control in endocrine disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.